Polymorphs of 3-
View Patent ↗The present invention relates to crystalline polymorphs of 3-O-(3′,3′-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine salt (“DSB•2NMG)”), pharmaceutical compositions of the same and use of the same as an active pharmaceutical agent in the treatment of HIV related disorders.
1. A crystalline form of 3-O-(3′,3′-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine (DSB•2NMG) having substantially the following X-ray powder diffraction pattern obtained with copper irradiation:
2-theta
I/I 0 (x100)
4.43
100
5.74
43
8.91
20
11.32
87
11.88
33
12.17
14
12.64
21
13.23
29
13.72
33
15.33
31
15.89
11
16.42
27
16.72
27
17.32
27
18.57
14
19.01
15
19.40
16
19.80
30
20.26
25
21.02
5
21.79
6
22.50
8
23.85
9.
2. The crystalline form of DSB•2NMG according to claim 1 , wherein the crystalline form contains less than about 25% of other solid forms of DSB•2NMG.
3. The crystalline form of DSB•2NMG according to claim 1 , wherein the crystalline form contains less than about 10% of other solid forms of DSB•2NMG.
4. The crystalline form of DSB•2NMG according to claim 1 , wherein the crystalline form is substantially phase pure.
5. The crystalline form of DSB•2NMG according to claim 1 , and further characterized by a Differential Scanning Calorimetry profile with an endotherm at about 152° C.
6. A process for preparing the crystalline form of DSB•2NMG of claim 1 comprising the steps of:
(a) preparing a saturated solution of DSB•2NMG in methanol;
(b) heating the solution above the saturation temperature to completely dissolve the DSB•2NMG;
(c) adjusting the temperature of the solution to a growth temperature; and,
(d) isolating the crystalline form of DSB•2NMG of claim 1 .
7. The process of claim 6 further comprising the step of introducing ethanol prior to heating the solution to an elevated temperature to completely dissolve the DSB•2NMG.
8. The process of claim 6 further comprising the step of seeding the solution of step (c) with a crystal of the crystalline form of DSB•2NMG of claim 1 .
9. The process of claim 6 , wherein the heated solution of step (b) is filtered prior to step (c).
10. A solid pharmaceutical composition comprising the crystalline form of DSB•2NMG according to claim 1 , and a pharmaceutically-acceptable carrier.
11. A method of treating a retroviral infection, comprising administering to patient in need thereof an effective amount of the crystalline form of DSB•2NMG according to claim 1 .
12. A drug substance comprising at least a detectable amount of the crystalline form of DSB•2NMG according to claim 1 .
13. A drug substance comprising about 90% to about 100% of the crystalline form of DSB2•NMG according to claim 1 .
14. A drug substance comprising substantially phase pure crystalline DSB•2NMG according to claim 1 .
15. The drug substance of claim 13 wherein the balance of the DSB•2NMG consists of one or more of (i) other crystalline forms of DSB•2NMG, (ii) a solvated crystalline form of DSB•2NMG and (iii) amorphous solid DSB•2NMG.
16. A crystalline form of DSB•2NMG characterized by an X-ray powder diffraction pattern substantially as depicted in FIG. 4 , and prepared by annealing the crystalline form of DSB•2NMG of claim 1 .
17. A crystalline form of 3-O-(3′,3′-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine (DSB•2NMG) having substantially the following x-ray powder diffraction pattern obtained with copper irradiation:
2-theta
I/I 0 (x100)
12.60
62
14.45
100
16.30
32
18.70
23
19.90
18
22.05
7
30.45
5
33.95
6.
18. A process for preparing the crystalline form of DSB•2NMG of claim 17 , comprising the steps of:
(a) preparing a saturated solution of DSB•2NMG in methyl ethyl ketone;
(b) heating said solution above the saturation temperature to completely dissolved the DSB•2NMG;
(c) adjusting the temperature of said solution to a growth temperature;
(d) evaporating the solvent; and, (e) isolating the crystalline form of DSB•2NMG of claim 17 .
19. The process of claim 18 further comprising the step of seeding the solution of step (c) with a crystal of the crystalline form of DSB•2NMG of claim 17 .
20. The process of claim 18 , wherein the heated solution of step (b) is filtered prior to step (c).
21. A solid pharmaceutical composition comprising the crystalline form of DSB•2NMG according to claim 16 , and a pharmaceutically-acceptable carrier.
22. A method of treating a retroviral infection, comprising administering to patient in need thereof an effective amount of the crystalline form of DSB•2NMG according to claim 16 .
23. A drug substance comprising at least a detectable amount of the crystalline form of DSB•2NMG according to claim 16 .
24. A drug substance comprising about 90% to about 100% of the crystalline form of DSB•2NMG according to claim 16 .
25. A drug substance comprising substantially phase pure crystalline DSB•2NMG according to claim 16 .
26. The drug substance of claim 24 wherein the balance of the DSB•2NMG consists of one or more of (i) other crystalline forms of DSB•2NMG, (ii) a solvated crystalline form of DSB•2NMG and (iii) amorphous solid DSB•2NMG.
27. A process of preparing the crystalline form of DSB•2NMG characterized by an X-ray powder diffraction pattern substantially as depicted in FIG. 4 , comprising the steps provided in claim 6 , and further comprising the step of annealing the isolated crystalline form of DSB•2NMG.
28. The process of claim 27 , wherein said annealing step comprises annealing at about 75° C. for about 2 days.